In relapsing AAV with rituximab-induced remission, maintenance rituximab vs. azathioprine reduced relapse at ≥32 mo.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 37523707.
- Also identified by DOI 10.7326/J23-0057.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Smith RM, Jones RB, Specks U, et al; RITAZAREM co-investigators. <b>Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.</b> Ann Rheum Dis. 2023;82:937-944. 36958796.
Medical subject headings
- Azathioprine
- Immunosuppressive Agents